Mohsin Aslam1, K Vijayasarathy2, Rupjyothi Talukdar3, M Sasikala4, D Nageshwar Reddy5. 1. Clinical Endocrinologist, Asian Institute of Gastroenterology, Somajiguda, Hyderabad, India. Electronic address: mohsin.aslam2602@gmail.com. 2. Asian Healthcare Foundation, Somajiguda, Hyderabad, India. 3. Clinical Pancreatologist, Asian Institute of Gastroenterology, Somajiguda, Hyderabad, India. 4. Director, Research, Institute of Basic Sciences and Translational Research, Asian Healthcare Foundation, Somajiguda, Hyderabad, India. 5. Chairman and Chief of Gastroenterology, Asian Institute of Gastroenterology, Somajiguda, Hyderabad, India.
Abstract
AIM: To study the incidence of glucose intolerance in CP patients without diabetes by performing oral glucose tolerance test (OGTT). METHODS: We screened consecutive Indian CP patients without diabetes over 6 months by performing OGTT and correlated with physical characteristics and glycated hemoglobin (HbA1c). We also compared c-peptide and pancreatic polypeptide response in different groups based on OGTT. Relevant statistical tests were performed. P < 0.05 was considered significant. RESULTS: Total of 171 patients were screened. Mean duration of CP was 5.03 ± 4.32 years. 55 were detected to have prediabetes and 40 DM on OGTT. CP patients with diabetes and prediabetes had significantly dilated pancreatic duct compared to non-diabetic CP (4.2 ± 2.7 mm, 3.6 ± 2.7 mm, 2.84 ± 2.25 mm; p = 0.018). Fasting blood glucose (FBS) and 2-hour OGTT were 109.35 ± 19.06, 97.47 ± 11.94, 85.24 ± 9.95 and 236.13 ± 31.42, 154.65 ± 19.53, 112.89 ± 16.32 in patients with DM, prediabetes and CP patients without diabetes (p < 0.0001). There was a good c-peptide response (p = 0.001) and reduced pancreatic polypeptide response (p = 0.003) in CP patients compared to controls. CONCLUSION: Early in the course of disease reduced pancreatic polypeptide response in the presence of good c-peptide response may result in development of DM.
AIM: To study the incidence of glucose intolerance in CPpatients without diabetes by performing oral glucose tolerance test (OGTT). METHODS: We screened consecutive Indian CPpatients without diabetes over 6 months by performing OGTT and correlated with physical characteristics and glycated hemoglobin (HbA1c). We also compared c-peptide and pancreatic polypeptide response in different groups based on OGTT. Relevant statistical tests were performed. P < 0.05 was considered significant. RESULTS: Total of 171 patients were screened. Mean duration of CP was 5.03 ± 4.32 years. 55 were detected to have prediabetes and 40 DM on OGTT. CPpatients with diabetes and prediabetes had significantly dilated pancreatic duct compared to non-diabetic CP (4.2 ± 2.7 mm, 3.6 ± 2.7 mm, 2.84 ± 2.25 mm; p = 0.018). Fasting blood glucose (FBS) and 2-hour OGTT were 109.35 ± 19.06, 97.47 ± 11.94, 85.24 ± 9.95 and 236.13 ± 31.42, 154.65 ± 19.53, 112.89 ± 16.32 in patients with DM, prediabetes and CPpatients without diabetes (p < 0.0001). There was a good c-peptide response (p = 0.001) and reduced pancreatic polypeptide response (p = 0.003) in CPpatients compared to controls. CONCLUSION: Early in the course of disease reduced pancreatic polypeptide response in the presence of good c-peptide response may result in development of DM.
Authors: Kevin Verhoeff; Sarah J Henschke; Braulio A Marfil-Garza; Nidheesh Dadheech; Andrew Mark James Shapiro Journal: Cells Date: 2021-01-30 Impact factor: 6.600